Easywell Biomedicals, Inc. Stocks

Operating across the United States and Asia, Easywell Biomedicals, Inc. focuses on the research, development, production, and sale of active pharmaceutical ingredients and over-the-counter drugs. The company's robust pipeline includes several therapeutic candidates: TLX-001 for anti-cough, TLX-005 for urinary incontinence, TLX-006 targeting breast cancer in pre-menopausal women, and TLX-007 and TLX-004 for depression. Other developments feature TLX-008 to prevent pneumocystis pneumonia, TLX-012 for epilepsy, TLX-017 for chronic angina, and TLX-011 for inflammatory rosacea lesions. Additionally, Easywell is advancing TWB-201, a patch for Parkinson's disease, along with TLX-501 for urinary conditions and TLX-502 for pneumonia. The firm also supplies medical devices. In partnership with Handa Pharmaceuticals and Handa Neuroscience, LLC, it is jointly developing TLX-050 for neurological disorder treatment. Founded in 1998, the company was previously known as Actherm Inc. before adopting the Easywell Biomedicals, Inc. name in July 2015, with its main office located in Hsinchu City, Taiwan.